ArticleIndian journal of gastroenterology : official journal of the Indian Society of Gastroenterology2026
Trends in the use of biologic agents and their persistence rates in inflammatory bowel disease in India.
Article in Indian journal of gastroenterology : official journal of the Indian Society of Gastroenterology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundBiologic agents revolutionized the treatment of inflammatory bowel disease (IBD), yet their usage rates in India have historically been among the lowest globally. This is primarily attributed to cost. Data is scarce regarding the proportion of Indian patients with IBD needing biologics, actually receiving them and the persistence with therapy.
aimTo evaluate the proportions of patients with IBD needing a biologic agent, receiving it, continuing or discontinuing it and reasons for these.
methodsThis observational cohort study enrolled 697 patients with IBD from a single center: 297 patients in a prospective arm and 400 patients in a retrospective arm. Demographic data and data on the need for biologics, receipt of therapy, duration of use and specific reasons for discontinuation were recorded.
resultsBiologics were indicated in 95 (31.9%) patients in the prospective arm and 16 (4%) in the retrospective arm. In the former, 80 (26.9%) patients received biologics whereas in the latter 13 (3.2%) received it. On follow-up, 51 (17.1%) in the prospective arm and 10 (2.5%) in the retrospective arm continued biologics for median duration of 13.5 (IQR 44) months and 18.5 (IQR 23) months, respectively. Major reasons for discontinuation in the prospective cohort included primary non-response and secondary loss of response (31%), whereas the retrospective arm was driven by non-affordability.
conclusionAbout 16% (111/697) of our patients with IBD needed biologics; of these, 16% (18/111) did not receive it. About a third of patients discontinued it. Strategies must focus on cost reduction and optimizing the use of biologics.
Indexed as
Identifiers
42768172What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.